Filing Flows

Filing Flows › Companies › Kura Oncology › Cash flow

Kura Oncology cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$63.2M in Q2 2026 · −$117M over twelve months

Operating cash flow−$62.5M
Capital spending−$656K
Free cash flow−$63.2M
Cash conversion cycle-1103 days

Analysis

In Q2 2026, Kura Oncology generated −$62.5M of operating cash flow and spent $656K on capital projects, leaving free cash flow of −$63.2M. That is $33.0M less than in Q2 2025 (−$30.2M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$112M; the largest uses were operating cash flow ($112M), capital spending ($5.7M); besides operations, cash came from other investing ($103M), shares issued ($2.7M); the cash balance fell by $11.7M.

Operating cash flow was −$62.5M against net income of −$68.3M. The largest differences: deferred revenue −$10.4M, accrued liabilities +$9.7M, stock-based pay +$8.2M.

Its cash conversion cycle was -1103 days (receivables 41 + inventory 623 − payables 1767): suppliers fund its working capital.

Free cash flow

Kura Oncology: free cash flow by quarterKura Oncology: free cash flow by quarter−$43.4MQ3 2024$269MQ4 2024−$72.2MQ1 2025−$30.2MQ2 2025−$83.2MQ3 2025$115MQ4 2025−$86.0MQ1 2026−$63.2MQ2 2026
Operating cash flow less capital spending.
Kura Oncology: operating cash flow against capital spendingKura Oncology: operating cash flow against capital spendingOperating cash flowCapital spending−$43.4M$0Q3 2024$269M$372KQ4 2024−$71.9M$292KQ1 2025−$28.8M$1.5MQ2 2025−$80.6M$2.6MQ3 2025$117M$2.3MQ4 2025−$85.9M$128KQ1 2026−$62.5M$656KQ2 2026
Latest (Q2 2026): Operating cash flow −$62.5M, Capital spending $656K.

Capital allocation, year by year

Kura Oncology: where the cash came from (up) and went (down), by fiscal yearKura Oncology: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$105MFY2021: Net borrowing −$7.2MFY2021: Shares issued $4.4MFY2021: Capital spending −$1.1M$4.4MFY2021FY2022: Operating cash flow −$110MFY2022: Net borrowing $10.0MFY2022: Shares issued $29.1MFY2022: Capital spending −$626K$39.1MFY2022FY2023: Operating cash flow −$125MFY2023: Shares issued $1.2MFY2023: Capital spending −$168K$1.2MFY2023FY2024: Operating cash flow $134MFY2024: Shares issued $8.6MFY2024: Capital spending −$472K$143MFY2024FY2025: Operating cash flow −$64.1MFY2025: Shares issued $1.8MFY2025: Capital spending −$6.6M$1.8MFY2025
Over these 5 years operating cash flow totalled −$269M; the largest uses were operating cash flow ($403M) and capital spending ($9.1M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$519M
Debt$9.7M
Net cash$509M
Due within a year$2.3M
Cash runway4.4 years

Kura Oncology is burning cash: its operations consume cash, a free cash flow of −$117M a year at the current rate against $519M of cash and investments: a runway of about 4.4 years; $2.3M of debt also comes due within a year, which the cash covers before any new financing.

Kura Oncology: debt maturities by year (FY2024)Kura Oncology: debt maturities by year (FY2024)$2.3MYear 1$3.8MYear 2$3.9MYear 3
Principal due in each year as disclosed in the annual report, against $519M of cash and investments now.

Where the cash came from and went

Kura Oncology: sources (+) and uses (−) of cash, Q2 2026Kura Oncology: sources (+) and uses (−) of cash, Q2 2026Other investing$92.9MOperating cash flow−$62.5MCash drawn (+) / kept (−)−$31.2MShares issued$1.5MCapital spending−$656K
Kura Oncology: sources (+) and uses (−) of cash, TTM to Q2 2026Kura Oncology: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$112MOther investing$103MCash drawn (+) / kept (−)$11.7MCapital spending−$5.7MShares issued$2.7M

From profit to cash

Kura Oncology: net income to operating cash flow, Q2 2026Kura Oncology: net income to operating cash flow, Q2 2026Net income−$68.3MDepreciation & amortization$369KStock-based pay$8.2MReceivables−$98KInventory−$1.6MPayables−$4.7MAccrued liabilities$9.7MDeferred revenue−$10.4MPrepaid and other assets$4.3MOperating cash flow−$62.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026416231767-1103
Q1 2026452162071-1811

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$62.5M−$656K$1.5M−$31.2M−$63.2M
Q1 2026−$85.9M−$128K$69K$110M−$86.0M
Q4 2025$117M−$2.3M$1.1M−$53.8M$115M
Q3 2025−$80.6M−$2.6M—−$13.3M−$83.2M
Q2 2025−$28.8M−$1.5M$515K−$30.7M−$30.2M
Q1 2025−$71.9M−$292K$143K$173M−$72.2M
Q4 2024$269M−$372K$807K−$175M$269M
Q3 2024−$43.4M—$2.2M−$4.3M−$43.4M

Kura Oncology: income statement and cash flow

Kura Oncology, Q2 2026: revenue $20.9M (+36% year over year), operating margin -349.8%. The chart follows the revenue to costs, profit and cash.

Kura Oncology: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.